Tags

Type your tag names separated by a space and hit enter

Amorphous magnesium carbonate nanoparticles with strong stabilizing capability for amorphous ibuprofen.
Int J Pharm. 2018 Sep 05; 548(1):515-521.IJ

Abstract

Formulating active pharmaceutical ingredients (APIs) in the amorphous state can increase their apparent aqueous solubility and dissolution rate and consequently improve their bioavailability. This study demonstrates, for the first time, the ability to stabilize an API in the amorphous state using a solid dispersion of magnesium carbonate nanoparticles within the API. Specifically, high proportions of ibuprofen were able to be stabilized in the amorphous state using as little as 17% wt/wt amorphous magnesium carbonate nanoparticles, and drug release rates 83 times faster than from the crystalline state were achieved. Biocompatibility of the nanoparticles was demonstrated in vitro using human dermal fibroblasts and stability of the nanocomposite formulation was verified with a storage time of six months. The success of this novel formulation provides a promising approach for achieving improved apparent solubility and enhanced bioavailability of drugs.

Authors+Show Affiliations

Nanotechnology and Functional Materials, Department of Engineering Science, Uppsala University, Uppsala 751 21, Sweden.Department of Pharmacy, Uppsala Biomedical Center, Uppsala University, Uppsala 751 23, Sweden.Applied Materials Science, Department of Engineering Science, Uppsala University, Uppsala 751 21, Sweden.Department of Pharmacy, Uppsala Biomedical Center, Uppsala University, Uppsala 751 23, Sweden.Nanotechnology and Functional Materials, Department of Engineering Science, Uppsala University, Uppsala 751 21, Sweden.Nanotechnology and Functional Materials, Department of Engineering Science, Uppsala University, Uppsala 751 21, Sweden. Electronic address: ken.welch@angstrom.uu.se.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29981897

Citation

Yang, Jiaojiao, et al. "Amorphous Magnesium Carbonate Nanoparticles With Strong Stabilizing Capability for Amorphous Ibuprofen." International Journal of Pharmaceutics, vol. 548, no. 1, 2018, pp. 515-521.
Yang J, Alvebratt C, Lu X, et al. Amorphous magnesium carbonate nanoparticles with strong stabilizing capability for amorphous ibuprofen. Int J Pharm. 2018;548(1):515-521.
Yang, J., Alvebratt, C., Lu, X., Bergström, C. A. S., Strømme, M., & Welch, K. (2018). Amorphous magnesium carbonate nanoparticles with strong stabilizing capability for amorphous ibuprofen. International Journal of Pharmaceutics, 548(1), 515-521. https://doi.org/10.1016/j.ijpharm.2018.07.021
Yang J, et al. Amorphous Magnesium Carbonate Nanoparticles With Strong Stabilizing Capability for Amorphous Ibuprofen. Int J Pharm. 2018 Sep 5;548(1):515-521. PubMed PMID: 29981897.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amorphous magnesium carbonate nanoparticles with strong stabilizing capability for amorphous ibuprofen. AU - Yang,Jiaojiao, AU - Alvebratt,Caroline, AU - Lu,Xi, AU - Bergström,Christel A S, AU - Strømme,Maria, AU - Welch,Ken, Y1 - 2018/07/05/ PY - 2018/05/11/received PY - 2018/07/03/revised PY - 2018/07/04/accepted PY - 2018/7/10/pubmed PY - 2018/11/16/medline PY - 2018/7/9/entrez KW - Amorphous KW - Dissolution KW - Ibuprofen KW - Magnesium carbonate KW - Nanocomposite KW - Nanoparticles KW - Solubility SP - 515 EP - 521 JF - International journal of pharmaceutics JO - Int J Pharm VL - 548 IS - 1 N2 - Formulating active pharmaceutical ingredients (APIs) in the amorphous state can increase their apparent aqueous solubility and dissolution rate and consequently improve their bioavailability. This study demonstrates, for the first time, the ability to stabilize an API in the amorphous state using a solid dispersion of magnesium carbonate nanoparticles within the API. Specifically, high proportions of ibuprofen were able to be stabilized in the amorphous state using as little as 17% wt/wt amorphous magnesium carbonate nanoparticles, and drug release rates 83 times faster than from the crystalline state were achieved. Biocompatibility of the nanoparticles was demonstrated in vitro using human dermal fibroblasts and stability of the nanocomposite formulation was verified with a storage time of six months. The success of this novel formulation provides a promising approach for achieving improved apparent solubility and enhanced bioavailability of drugs. SN - 1873-3476 UR - https://www.unboundmedicine.com/medline/citation/29981897/Amorphous_magnesium_carbonate_nanoparticles_with_strong_stabilizing_capability_for_amorphous_ibuprofen_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5173(18)30489-7 DB - PRIME DP - Unbound Medicine ER -